What Dulaglutide is
Dulaglutide is a long-acting GLP-1 receptor agonist used in approved metabolic disease contexts.
Dulaglutide is grouped under Fat Loss + GLP-1s / Approved / Clinical on PeptideFactCheck because it rounds out the GLP-1 category and gives readers a broader view beyond the newest weight-loss drugs.
The useful starting point is to separate the molecule itself from the internet story around it. It is part of the broader GLP-1 family people compare to semaglutide.
Why people keep looking it up
People know dulaglutide as a GLP-1 medicine for metabolic disease.
Dulaglutide activates GLP-1 receptor signaling in a long-acting format.
Dulaglutide tends to stay in the conversation because it touches a familiar public theme: glp-1 receptor, glucose, and incretin. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Approved use exists for specific indications, not every weight-loss claim online.
Human trials and official labels support approved uses.
Mechanistic rationale follows GLP-1 receptor pharmacology.
Why this page carries the current tier: Approved drug with official source trail.
The current seed trail for Dulaglutide is pulling from 1 labels source, 1 regulatory source, and 1 literature source.
Safety, limits, and regulatory context
Risk discussion should stay anchored to current labeling.
FDA-approved dulaglutide products exist for specific indications.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for Dulaglutide. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Clinical trial snapshot
The current ClinicalTrials.gov intervention query for Dulaglutide returns 135 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
Literature snapshot
The current PubMed query for Dulaglutide returns 1219 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Label and regulatory records
For approved or clinically developed peptides, the page now pulls in official labeling and FDA-facing records where they exist. That makes the regulatory section materially more useful than a generic approved or not-approved tag.
- Brand names
- TRULICITY
- Generic names
- DULAGLUTIDE
- Routes
- SUBCUTANEOUS
- Application numbers
- BLA125469
Indications and usage. 1 INDICATIONS AND USAGE TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disea...
Warnings and cautions. 5 WARNINGS AND PRECAUTIONS Thyroid C-cell Tumors: See Boxed Warning ( 5.1 ). Pancreatitis: Has been reported in clinical trials. Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed ( 5.2 ). Hypoglycemia: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing the dose of insulin secretagogue or i...
Contraindications. 4 CONTRAINDICATIONS TRULICITY is contraindicated in patients with: Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions ( 5.1 )] . Serious hypersensitivity reaction to dulaglutide or to any of the product components. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have...
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.